expressed, PD-L1 was up-regulated in NSCLC compared with the adjacent tissues. CD8+ TILs could be seen in tumor stroma and nest. With univariate analysis, we found that the down-expression of MHC-I had an association with poor relapse-free survival (RFS) and overall survival (OS) in NSCLC patients (P ¼ 0.007 and P ¼ 0.001). RFS and OS in PD-L1À group tended to be longer than that of PD-L1+ group, but the difference was not significant (P > 0.05). Based on the distribution of CD8+ TILs, patients were divided into three groups: immune-inflamed group, immune-excluded group and immune-desert group. RFS and OS of patients with the immune-inflamed phenotype (CD8 inflamed ) were longer than patients with the immune-excluded and immune-desert phenotype (CD8 noninflamed ) (P ¼ 0.013 and P ¼ 0.015). Besides, patients were divided into four subgroups based on the PD-L1 and CD8+ TILs expression: PD-L1+/CD8
expressed, PD-L1 was up-regulated in NSCLC compared with the adjacent tissues. CD8+ TILs could be seen in tumor stroma and nest. With univariate analysis, we found that the down-expression of MHC-I had an association with poor relapse-free survival (RFS) and overall survival (OS) in NSCLC patients (P ¼ 0.007 and P ¼ 0.001). RFS and OS in PD-L1À group tended to be longer than that of PD-L1+ group, but the difference was not significant (P > 0.05). Based on the distribution of CD8+ TILs, patients were divided into three groups: immune-inflamed group, immune-excluded group and immune-desert group. RFS and OS of patients with the immune-inflamed phenotype (CD8 inflamed ) were longer than patients with the immune-excluded and immune-desert phenotype (CD8 noninflamed ) (P ¼ 0.013 and P ¼ 0.015). Besides, patients were divided into four subgroups based on the PD-L1 and CD8+ Background: MicroRNAs (miRNAs) are small non-coding RNAs that play a crucial role in pathogenesis of human cancers. Several miRNAs have been shown to involve in regulation of tumor development and metastasis of lung cancer through alteration of gene networks. The aim of this study was to identify a panel of miRNAs as potential diagnostic and therapeutic target in lung cancer. Method: Quantitative reversetranscriptase PCR was applied to evaluate the expression of selected 12 cancer-associated microRNAs in 79 patients' samples with primary lung cancer and matched metastatic lymph node tissues. Protein expression were detected by immunoblotting. Cell migration, invasion and invadopodia formation were assessed in vitro by wound-healing, transwell assay and immunofluorescence, respectively. The dual-luciferase reporter assay was used to identify the direct target of miRNA. The Kaplan-Meier and log-rank test were performed to quantify the survival functions in two groups. Results: miR-145 was significantly lower in LN-positive NSCLC (P < 0.05), while expression of miR-10b was significantly higher (P < 0.05). Expression of both miR-145 and miR-10b was correlated with lymph node metastasis in NSCLC (both Ps < 0.001). Functional experiments reveal that miR-10b facilitated the migration and invasion of lung cancer cell line A549, while miR-145 suppressed the migration and invasion capacity of A549 in vitro. Additionally, low miR-146b-5p expression level was associated with poor prognosis in NSCLC patients, and miR-146b was an independent prognostic factor for NSCLC patients. In vitro gain-of-function and lossof-function assays revealed that miR-146b-5p suppressed cell proliferation, clonogenicity, migration/ invasion and also induced G1 arrest in NSCLC. Furthermore, MiR-182 inhibits the epithelial to mesenchymal transition and metastasis of lung cancer cells by targeting the Met gene via inactivation of Met/AKT/Snail in non-small cell lung cancer (NSCLC) cells. Moreover, miR-182 negatively regulated invadopodia function, and suppressed extracellular matrix(ECM) degradation in lung cancer cells via suppression of the Cdc42/N-WASP pathway by targeting cortactin. Conclusion: Collectively, our data revealed that this panel of four-miRNA signature may be useful predictors and therapeutic targets in NSCLC. Sep-2018, 32 patients with pathologically confirmed advanced NSCLC who failed to second line or beyond treatment were enrolled in the study. All the patients were given Osimertinib Mesylate Tablets 80mg/d orally until disease progression. Clinical efficacy and adverse reactions were observed. Kaplan-Meier method was used for survival analysis.
Results: According to the Response Evaluation Criteria in Solid Tumors (RECIST) standard, all the patients can be evaluated for therapeutic effects. Complete response (CR) rate was 0% (0/60), partial response (PR)rate was 50.00% (16/32), stable disease (SD) rate 46.88 (15/32), and progressive disease (PD) rate 3.12% (1/32). The objective response rate (CR + PR) and the disease control rate (CR + PR + SD) were 50.00% and 96.88% (31/320), respectively. The median progression-free survival time was 8.0 months. Main adverse reactions were rash and diarrhea. Conclusion: Administration of Osimertinib Mesylate Tablets in advanced NSCLC patients after failure to second-line or beyond treatment is still beneficial in terms of higher disease control rate and better survival, and its adverse reactions are tolerable. Keywords: Osimertinib Mesylate Tablets, nsclc, Clinical efficacy
